CN107260704B - 一种粪肠球菌微胶囊及其制备方法 - Google Patents
一种粪肠球菌微胶囊及其制备方法 Download PDFInfo
- Publication number
- CN107260704B CN107260704B CN201710429401.2A CN201710429401A CN107260704B CN 107260704 B CN107260704 B CN 107260704B CN 201710429401 A CN201710429401 A CN 201710429401A CN 107260704 B CN107260704 B CN 107260704B
- Authority
- CN
- China
- Prior art keywords
- enterococcus faecalis
- microcapsules
- microcapsule
- solution
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003094 microcapsule Substances 0.000 title claims abstract description 72
- 241000194032 Enterococcus faecalis Species 0.000 title claims abstract description 48
- 229940032049 enterococcus faecalis Drugs 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000000463 material Substances 0.000 claims abstract description 28
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000000661 sodium alginate Substances 0.000 claims abstract description 21
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 21
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 21
- 238000003756 stirring Methods 0.000 claims abstract description 17
- 239000000725 suspension Substances 0.000 claims abstract description 16
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims abstract description 14
- 229920002581 Glucomannan Polymers 0.000 claims abstract description 14
- 229920002752 Konjac Polymers 0.000 claims abstract description 14
- 229940046240 glucomannan Drugs 0.000 claims abstract description 14
- 239000000252 konjac Substances 0.000 claims abstract description 14
- 238000001914 filtration Methods 0.000 claims abstract description 13
- 238000002156 mixing Methods 0.000 claims abstract description 13
- 239000002131 composite material Substances 0.000 claims abstract description 11
- 230000001954 sterilising effect Effects 0.000 claims abstract description 11
- 244000247812 Amorphophallus rivieri Species 0.000 claims abstract description 10
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims abstract description 10
- 235000010485 konjac Nutrition 0.000 claims abstract description 10
- 230000001580 bacterial effect Effects 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract description 8
- 239000003921 oil Substances 0.000 claims abstract description 7
- 235000019198 oils Nutrition 0.000 claims abstract description 7
- 235000012424 soybean oil Nutrition 0.000 claims abstract description 7
- 239000003549 soybean oil Substances 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims description 40
- 239000012530 fluid Substances 0.000 claims description 19
- 239000001963 growth medium Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 12
- 230000002496 gastric effect Effects 0.000 claims description 10
- 230000000968 intestinal effect Effects 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 238000009630 liquid culture Methods 0.000 claims description 9
- 238000007865 diluting Methods 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 238000004945 emulsification Methods 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- 239000001888 Peptone Substances 0.000 claims description 6
- 108010080698 Peptones Proteins 0.000 claims description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 6
- 235000015278 beef Nutrition 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 235000019319 peptone Nutrition 0.000 claims description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
- 229920000136 polysorbate Polymers 0.000 claims description 6
- 229920000053 polysorbate 80 Polymers 0.000 claims description 6
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 230000003068 static effect Effects 0.000 claims description 4
- 229920001817 Agar Polymers 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- 102000057297 Pepsin A Human genes 0.000 claims description 3
- 108090000284 Pepsin A Proteins 0.000 claims description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 3
- 102000004142 Trypsin Human genes 0.000 claims description 3
- 108090000631 Trypsin Proteins 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- 229940099596 manganese sulfate Drugs 0.000 claims description 3
- 239000011702 manganese sulphate Substances 0.000 claims description 3
- 235000007079 manganese sulphate Nutrition 0.000 claims description 3
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 3
- 239000002609 medium Substances 0.000 claims description 3
- 229940111202 pepsin Drugs 0.000 claims description 3
- 239000001632 sodium acetate Substances 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- 239000001393 triammonium citrate Substances 0.000 claims description 3
- 235000011046 triammonium citrate Nutrition 0.000 claims description 3
- 239000012588 trypsin Substances 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 238000007790 scraping Methods 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 abstract description 36
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 13
- 239000004310 lactic acid Substances 0.000 abstract description 11
- 235000014655 lactic acid Nutrition 0.000 abstract description 11
- 239000011248 coating agent Substances 0.000 abstract description 10
- 238000000576 coating method Methods 0.000 abstract description 10
- 210000004211 gastric acid Anatomy 0.000 abstract description 7
- 239000003431 cross linking reagent Substances 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000001094 effect on targets Effects 0.000 abstract description 3
- 239000011162 core material Substances 0.000 description 6
- 244000144972 livestock Species 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 244000144977 poultry Species 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000008944 intestinal immunity Effects 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000002068 microbial inoculum Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/10—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a carbohydrate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/225—Faecalis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Animal Husbandry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Physiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明提供一种粪肠球菌微胶囊及其制备方法，所述制备方法是将海藻酸钠和魔芋胶作为复合壁材，溶解灭菌后和目标菌悬液混合并搅拌均匀，然后加入到大豆油中，在磁力搅拌器上搅拌直到完全乳化，然后沿器壁快速加入CaCl2溶液，低速搅拌至水油两相分离，最后低速离心收集微胶囊，用CaCl2溶液漂洗后，同条件下收集微胶囊并放置4℃过夜。最后用无菌纱布滤去多余水分后制得粪肠球菌微胶囊。本发明制备的微胶囊具有更好的物理形态以及对目标菌的保护效果，所用制备方法操作简单，便于扩大生产；所用壁材天然安全，并对胃酸具有较强抵抗性能；制备过程中未使用毒性交联剂，保证了包被乳酸菌的活性。
Description
技术领域
本发明属于微胶囊技术领域，具体地说，涉及一种粪肠球菌微胶囊及其制备方法。
背景技术
人类利用乳酸菌的历史源远流长，经过多年的研究发展，大多数乳酸菌本身及其代谢活动已在食品、工业、农业、医药和科研上发挥着重要功能。尤其是在医药上，现有大量研究表明乳酸菌通过改善动物肠道菌群情况，在降低血压、治疗糖尿病、抑制肥胖以及调节情绪等方面发挥着不可或缺的作用。再加上其能产生多种代谢产物抑制病原菌，维持动物消化道菌群平衡；具有营养代谢作用，促进畜禽生长；增强畜禽肠道免疫功能；缓解畜禽不良应激反应；改善畜禽生存环境等作用，使乳酸菌成为抗菌药物的替代品成为可能。
然而上述功能都需在足够数量(106CFU/g)的活菌存在的情况下才能实现，但是大多数乳酸菌不能耐受动物消化道中胃酸、胆盐等不良环境条件的作用，并且在颗粒饲料加工中无法耐受制粒时的高温、压力和剪切力，以及运输和存储过程中易受温度、挤压、氧气的影响，致使活性大大降低甚至死亡，严重影响了活菌制剂的效价及其应有的益生特性。
微胶囊包被技术是保护乳酸菌活力最为有效和实用的方法之一。它主要通过高分子材料的聚合作用，将固体、液体或气体等芯材物质包囊成直径为5-200μm的半透性或密封囊膜，从而改善芯材的物理性质(物质密度、流动性、可压性、分散性等)，并保护芯材免受外界氧气、温度、水分、紫外线等不良因素的影响，提高芯材物质的稳定性和贮藏期，并便于贮存、运输与使用；同时，可以有针对性地选择合适囊膜物质，控制芯材的释放时间和地点，最大限度发挥芯材的功效。有研究表明，经相应物质包被后的乳酸菌不但能够正常发酵，还可以获得较高的活菌数量；同时，耐受胃酸、胆盐以及不利储存条件的能力大大提高。
但是，目前已有的微胶囊包被技术和产品多存在表面多孔、包被材料不耐受胃酸、交联剂有毒以及技术流程不适合大规模生产应用等不利因素，严重影响了所包被乳酸菌的活性及其产品的产业化和应用。
发明内容
本发明的目的是提供一种新型的粪肠球菌微胶囊及其制备方法。
为了实现本发明目的，本发明采用乳化法作为基本技术手段，利用具有较好成膜特性、又具有益生元作用的魔芋胶和海藻酸钠形成的复合壁材，对目标菌进行微胶囊包被，使形成的微胶囊具有较好的物理性质和机械性能，尤其是在通过胃肠液后保持较高目标菌活性方面取得了较好的保护效果，对促进乳酸菌微胶囊产品的实际应用具有重要意义。
本发明提供一种粪肠球菌微胶囊的制备方法，包括以下步骤：
1)粪肠球菌菌悬液的制备；
2)海藻酸钠-魔芋胶复合壁材溶液的制备；
3)将1)的菌悬液与2)的壁材溶液混匀，然后加入到含有吐温80的大豆油中，搅拌至完全乳化；沿盛有上述乳化液的容器壁快速加入CaCl2溶液，搅拌至水油两相分离，然后离心收集水相中的微胶囊，用CaCl2溶液漂洗收集的微胶囊数次，然后将微胶囊放置于4℃过夜，最后用无菌纱布滤去多余水分后，制得粪肠球菌微胶囊。
其中，步骤1)配制好的粪肠球菌菌悬液中活菌数为4.50×1010-10.50×1010cfu/mL，优选5.09×1010cfu/mL。
步骤1)粪肠球菌菌悬液的制备方法如下：将粪肠球菌划线于MRS固体培养基，37℃倒置培养24h后，挑取单菌落或刮取一环接入MRS液体培养基中，37℃静置培养24h；然后取上述培养液1mL接种于50mL MRS液体培养基中，37℃静置培养10h；培养液在4℃、8500×g条件下离心10min，菌体沉淀用生理盐水重悬，即得粪肠球菌菌悬液。
本发明所述的MRS固体平板培养基是由蛋白胨10.0g，牛肉粉5.0g，酵母粉4.0g，葡萄糖20.0g，吐温80 1.0mL，CH3COONa·3H2O5.0g，K2HPO4·7H2O 2.0g，柠檬酸三铵2.0g，MgSO4·7H2O 0.2g，MnSO4·4H2O 0.05g，琼脂15.0g，加蒸馏水溶解，定容至1000mL，pH6.2±0.2，115℃蒸汽灭菌20min，倾倒平板制成。
所述的MRS液体培养基是由蛋白胨10.0g，牛肉粉10.0g，酵母粉5.0g，葡萄糖20.0g，硫酸镁0.1g，乙酸钠5.0g，柠檬酸铵2.0g，磷酸氢二钾2.0g，硫酸锰0.05g，吐温801.0mL，加蒸馏水溶解，定容至1000mL，pH7.3±0.2，分装到三角瓶，115℃蒸汽灭菌20min制成。
步骤2)海藻酸钠-魔芋胶复合壁材溶液的制备方法如下：向海藻酸钠的水溶液中加入魔芋胶，加蒸馏水定容至100mL，灭菌后作为复合壁材溶液备用。所述复合壁材溶液中海藻酸钠和魔芋胶的浓度分别为25g/L和2.5g/L。
步骤3)具体为：将1)的菌悬液2mL，与2)的壁材溶液混匀，然后加入到300mL含有0.5w/v％吐温80的大豆油中，在磁力搅拌器上以500rpm/min的转速搅拌30min直到完全乳化，然后沿器壁以20mL/s的速度加入100mL 0.1M的CaCl2溶液，低速搅拌至水油两相分离(30min左右)，最后在350×g(1950rpm)条件下离心10min收集水相中的微胶囊，并用0.1M的CaCl2溶液漂洗微胶囊2次，然后将微胶囊放置于4℃过夜(12h)；最后用8层无菌纱布滤去多余水分后，制得粪肠球菌微胶囊。
本发明所述粪肠球菌包括但不限于粪肠球菌(Enterococcus faecalis)CGMCC1.2024。
在本发明的一个具体实施方式中，所述粪肠球菌微胶囊的制备方法如下：
(1)出发菌株粪肠球菌划线于MRS固体培养基，37℃倒置培养24h后，挑取单菌落或刮取一环接入MRS液体培养基中，37℃静置培养24h。然后取上述培养液1mL接种于50mL MRS液体培养基中(50mL三角瓶)，37℃静置培养10h。培养液在4℃、8500×g(9450rpm)条件下离心10min，沉淀重悬浮后其活菌数为5.09×1010cfu/mL。
(2)在2.5％海藻酸钠(w/v)基础上，加入0.25％的魔芋胶(w/v)，定容100mL，115℃灭菌20min后，冷却至38-40℃，作为壁材溶液备用。壁材溶液中海藻酸钠和魔芋胶的浓度分别为25g/L和2.5g/L。
(3)将(1)中菌悬液2mL与(2)中壁材溶液混合，搅拌均匀后，加入到300mL大豆油中(含有0.5％吐温80(w/v))，在磁力搅拌器上以500rpm/min的转速搅拌30min直到完全乳化，然后沿器壁快速(20mL/s)加入100mL 0.1M的CaCl2溶液，低速搅拌至水油两相分离(30min左右)，最后在350×g(1950rpm)，10min条件下离心收集微胶囊，并用0.1M的CaCl2溶液漂洗2次，同条件下收集微胶囊放置4℃过夜(12h)。8层无菌纱布滤去多余水分后，制得粪肠球菌微胶囊。
(4)收获粪肠球菌微胶囊，并对微胶囊进行形态观察、粒径大小、包埋效率及在胃肠液中对目标菌的保护效果进行评估，同时和单独海藻酸钠包被微胶囊的包被效果进行对比分析。
本发明还提供按照所述方法制备的粪肠球菌微胶囊。本发明制备的微胶囊具有更佳的圆球度，以及光滑和致密的表面结构(表面可见的颗粒状结构是粘附在表面的菌体)，有效填充了单独海藻酸钠微胶囊形成的多孔结构；同时，本发明制备的微胶囊具有33.75±1.08％的包被效率和453.79μm的直径大小。上述制备方法同样适用于嗜酸乳杆菌微胶囊的制备。
本发明进一步提供所述粪肠球菌微胶囊在抗模拟胃液和/或模拟肠液环境中的应用。将所述粪肠球菌微胶囊加入到模拟胃液和/或模拟肠液的环境中，26.5-37℃孵育2-4h。
其中，所述模拟胃液为：取浓度为1mol/ml的稀盐酸，加水稀释，将pH调至1.5；每100ml液体中加入1g胃蛋白酶，混匀，用0.22μm的无菌滤头过滤即得。
所述模拟肠液为：取KH2PO4 6.8g加水500ml溶解，用0.4％的NaOH溶液回调pH至6.8，每100ml液体中加入1g胰蛋白酶，混匀，用0.22μm的无菌滤头过滤即得。
本发明制备的微胶囊在pH为1.5的模拟胃液中2h后，其包被目标菌的活菌数达到3.0×107cfu/g，与单独海藻酸钠包被的目标菌活菌数提高了近20倍(1.74×106cfu/g)。在pH为6.8的模拟肠液中4h后，本发明制备的微胶囊包被目标菌的活菌数达到1.79×109cfu/g，与单独海藻酸钠包被的目标菌活菌数提高了近1.6倍(1.11×109cfu/g)。
(3)本发明所用方法操作简单，便于扩大生产；同时所用壁材天然安全，并对胃酸具有较强抵抗性能；同时制备过程中未使用有毒性交联剂，保证了包被乳酸菌的活性。
本发明提供的粪肠球菌微胶囊具有更好的物理形态以及对目标菌的保护效果，同时本发明采用的制备方法操作简单，便于扩大生产；所用壁材天然安全，并对胃酸具有较强抵抗性能；制备过程中未使用毒性交联剂，保证了包被乳酸菌的活性。
附图说明
图1为本发明实施例1中微胶囊的形态观察结果；其中，a和b分别为单独海藻酸钠微胶囊的整体和局部电镜图；c和d分别为本发明制备的粪肠球菌微胶囊的整体和局部电镜图。
具体实施方式
以下实施例用于说明本发明，但不用来限制本发明的范围。若未特别指明，实施例中所用的技术手段为本领域技术人员所熟知的常规手段，所用原料均为市售商品。
实施例1粪肠球菌微胶囊及其制备方法
本实施例所用的菌株为粪肠球菌(Enterococcus faecalis CGMCC1.2024)。
(1)蛋白胨10.0g，牛肉粉5.0g，酵母粉4.0g，葡萄糖20.0g，吐温80 1.0mL，CH3COONa·3H2O 5.0g，K2HPO4·7H2O 2.0g，柠檬酸三铵2.0g，MgSO4·7H2O 0.2g，MnSO4·4H2O 0.05g，琼脂15.0g，加蒸馏水溶解，定容至1000mL，pH6.2±0.2，115℃蒸汽灭菌20min，倾倒平板，制成活化菌体的固体平板培养基。
蛋白胨10.0g，牛肉粉10.0g，酵母粉5.0g，葡萄糖20.0g，硫酸镁0.1g，乙酸钠5.0g，柠檬酸铵2.0g，磷酸氢二钾2.0g，硫酸锰0.05g，吐温80 1.0mL，加蒸馏水溶解，定容至1000mL，pH7.3±0.2，分装到三角瓶，115℃蒸汽灭菌20min，制成菌体种子液和扩大培养液体培养基。
(2)出发菌株粪肠球菌划线于MRS固体培养基，37℃倒置培养24h后，挑取单菌落或刮取一环接入MRS液体培养基中，37℃静置培养24h。然后取上述培养液1mL接种于50mL MRS液体培养基中(50mL三角瓶)，37℃静置培养10h。培养液在4℃、8500×g(9450rpm)条件下离心10min，沉淀重悬浮后其活菌数为5.09×1010cfu/mL。
(3)在2.5％海藻酸钠(w/v)基础上，加入0.25％的魔芋胶(w/v)，定容100mL，115℃灭菌20min后，冷却至38-40℃，作为壁材溶液备用。壁材溶液中海藻酸钠和魔芋胶的浓度分别为25g/L和2.5g/L。
(4)将(1)中菌悬液2mL与(2)中壁材溶液混合，搅拌均匀后，加入到300mL大豆油中(含有0.5％吐温80(w/v))，在磁力搅拌器上以500rpm/min的转速搅拌30min直到完全乳化，然后沿器壁快速(20mL/s)加入100mL 0.1M的CaCl2溶液，低速搅拌至水油两相分离(30min左右)，最后在350×g(1950rpm)，10min条件下离心收集微胶囊，并用0.1M的CaCl2溶液漂洗2次，同条件下收集微胶囊放置4℃过夜(12h)。8层无菌纱布滤去多余水分后，制得粪肠球菌微胶囊。
实施例2粪肠球菌微胶囊的形态及性能分析
收获实施例1制备的粪肠球菌微胶囊，并对微胶囊进行形态观察、粒径大小、包埋效率及在胃肠液中对目标菌的保护效果进行评估，同时和单独海藻酸钠包被微胶囊的包被效果进行对比分析。
实施例1中制备的微胶囊与单独海藻酸钠制备的微胶囊相比：
1、本发明制备的微胶囊具有更佳的圆球度，以及光滑和致密的表面结构(表面可见的颗粒状结构是粘附在表面的菌体)，有效填充了单独海藻酸钠微胶囊形成的多孔结构(图1)。
2、本发明制备的微胶囊具有33.75±1.08％的包被效率和453.79μm的直径大小。
3、本发明制备的微胶囊在pH为1.5的模拟胃液中2h后，其包被目标菌的活菌数达到3.0×107cfu/g，与单独海藻酸钠包被的目标菌活菌数提高了近20倍(1.74×106cfu/g)；而在pH为6.8的模拟肠液中4h后，本发明所述制备的微胶囊包被目标菌的活菌数达到1.79×109cfu/g，与单独海藻酸钠包被的目标菌活菌数提高了近1.6倍(1.11×109cfu/g)。
其中，所述模拟胃液为：取浓度为1mol/ml的稀盐酸，加水稀释，将pH调至1.5；每100ml液体中加入1g胃蛋白酶，混匀，用0.22μm的无菌滤头过滤即得。
所述模拟肠液为：取KH2PO4 6.8g加水500ml溶解，用0.4％的NaOH溶液回调pH至6.8，每100ml液体中加入1g胰蛋白酶，混匀，用0.22μm的无菌滤头过滤即得。
本发明采用的制备方法操作简单，便于扩大生产；所用壁材天然安全，并对胃酸具有较强抵抗性能；同时制备过程中未使用有毒性交联剂，保证了包被乳酸菌的活性。
虽然，上文中已经用一般性说明及具体实施方案对本发明作了详尽的描述，但在本发明基础上，可以对之做一些修改或改进，这对本领域技术人员而言是显而易见的。因此，在不偏离本发明精神的基础上所做的这些修改或改进，均属于本发明要求保护的范围。
Claims (8)
1.粪肠球菌微胶囊的制备方法，其特征在于，包括以下步骤：
1)粪肠球菌菌悬液的制备；
2)海藻酸钠-魔芋胶复合壁材溶液的制备；
3)将1)的菌悬液与2)的壁材溶液混匀，然后加入到含有吐温80的大豆油中，搅拌至完全乳化；沿盛有上述乳化液的容器壁快速加入CaCl2溶液，搅拌至水油两相分离，然后离心收集水相中的微胶囊，用CaCl2溶液漂洗收集的微胶囊数次，然后将微胶囊放置于4℃过夜，最后用无菌纱布滤去多余水分后，制得粪肠球菌微胶囊；
步骤1)配制好的粪肠球菌菌悬液中活菌数为4.50×1010-10.50×1010cfu/mL；
步骤2)海藻酸钠-魔芋胶复合壁材溶液的制备方法如下：向海藻酸钠的水溶液中加入魔芋胶，加蒸馏水定容至100mL，灭菌后作为复合壁材溶液备用；所述复合壁材溶液中海藻酸钠和魔芋胶的浓度分别为25g/L和2.5g/L；
步骤3)具体为：将1)的菌悬液2mL，与2)的壁材溶液混匀，然后加入到300mL含有0.5w/v％吐温80的大豆油中，在磁力搅拌器上以500rpm的转速搅拌30min直到完全乳化，然后沿器壁以20mL/s的速度加入100mL 0.1M的CaCl2溶液，低速搅拌至水油两相分离，最后在350×g条件下离心10min收集水相中的微胶囊，并用0.1M的CaCl2溶液漂洗微胶囊2次，然后将微胶囊放置于4℃过夜；最后用8层无菌纱布滤去多余水分后，制得粪肠球菌微胶囊。
2.根据权利要求1所述的方法，其特征在于，步骤1)配制好的粪肠球菌菌悬液中活菌数为5.09×1010cfu/mL。
3.根据权利要求1所述的方法，其特征在于，步骤1)粪肠球菌菌悬液的制备方法如下：将粪肠球菌划线于MRS固体培养基，37℃倒置培养24h后，挑取单菌落或刮取一环接入MRS液体培养基中，37℃静置培养24h；然后取上述培养液1mL接种于50mL MRS液体培养基中，37℃静置培养10h；培养液在4℃、8500×g条件下离心10min，菌体沉淀用生理盐水重悬，即得粪肠球菌菌悬液。
4.根据权利要求3所述的方法，其特征在于，步骤1)所述的MRS固体培养基是由蛋白胨10.0g，牛肉粉5.0g，酵母粉4.0g，葡萄糖20.0g，吐温80 1.0mL，CH3COONa·3H2O 5.0g，K2HPO4·7H2O 2.0g，柠檬酸三铵2.0g，MgSO4·7H2O 0.2g，MnSO4·4H2O 0.05g，琼脂15.0g，加蒸馏水溶解，定容至1000mL，pH6.2±0.2，115℃蒸汽灭菌20min，倾倒平板制成；
所述的MRS液体培养基是由蛋白胨10.0g，牛肉粉10.0g，酵母粉5.0g，葡萄糖20.0g，硫酸镁0.1g，乙酸钠5.0g，柠檬酸铵2.0g，磷酸氢二钾2.0g，硫酸锰0.05g，吐温80 1.0mL，加蒸馏水溶解，定容至1000mL，pH7.3±0.2，分装到三角瓶，115℃蒸汽灭菌20min制成。
5.根据权利要求1-4任一项所述的方法，其特征在于，所述粪肠球菌为粪肠球菌(Enterococcus faecalis)CGMCC 1.2024。
6.根据权利要求1-5任一项所述方法制备的粪肠球菌微胶囊。
7.权利要求6所述粪肠球菌微胶囊在抗模拟胃液和/或模拟肠液环境中的应用。
8.根据权利要求7所述的应用，其特征在于，将所述粪肠球菌微胶囊加入到模拟胃液和/或模拟肠液的环境中，26.5-37℃孵育2-4h；
其中，所述模拟胃液为：取浓度为1mol/ml的稀盐酸，加水稀释，将pH调至1.5；每100ml液体中加入1g胃蛋白酶，混匀，用0.22μm的无菌滤头过滤即得；
所述模拟肠液为：取KH2PO4 6.8g加水500ml溶解，用0.4％的NaOH溶液回调pH至6.8，每100ml液体中加入1g胰蛋白酶，混匀，用0.22μm的无菌滤头过滤即得。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710429401.2A CN107260704B (zh) | 2017-06-08 | 2017-06-08 | 一种粪肠球菌微胶囊及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710429401.2A CN107260704B (zh) | 2017-06-08 | 2017-06-08 | 一种粪肠球菌微胶囊及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107260704A CN107260704A (zh) | 2017-10-20 |
| CN107260704B true CN107260704B (zh) | 2020-02-11 |
Family
ID=60066506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710429401.2A Active CN107260704B (zh) | 2017-06-08 | 2017-06-08 | 一种粪肠球菌微胶囊及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107260704B (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107828682A (zh) * | 2017-11-06 | 2018-03-23 | 四川恒通动保生物科技有限公司 | 一种乳酶生的发酵培养基及应用 |
| CN109971670B (zh) * | 2019-02-01 | 2023-01-24 | 温州医科大学 | 粪肠球菌、其培养基及牛奶中抗生素残留的检测方法及应用 |
| CN110129217B (zh) * | 2019-04-22 | 2021-07-23 | 华中农业大学 | 一种提高乳酸菌耐热性能的方法及应用 |
| CN110433231A (zh) * | 2019-09-16 | 2019-11-12 | 上海赫尔伯生物科技有限公司 | 调节内分泌、补气血、祛皱美白、抗衰老胶囊及其制备方法 |
| CN111088194B (zh) * | 2020-01-16 | 2022-09-20 | 盛锦合生物科技(江苏)有限公司 | 一株粪肠球菌及其应用 |
| CN112206242A (zh) * | 2020-08-05 | 2021-01-12 | 内蒙古农业大学 | 杀动物寄生虫虫卵的真菌微胶囊及其制备方法和应用 |
| CN112826836A (zh) * | 2021-01-08 | 2021-05-25 | 深圳未知君生物科技有限公司 | 一种粪菌口服制剂及其制备方法 |
-
2017
- 2017-06-08 CN CN201710429401.2A patent/CN107260704B/zh active Active
Non-Patent Citations (1)
| Title |
|---|
| Milk-alginate microspheres: Protection and delivery of Enterococcus faecalis HZNU P2;Lu-E. Shi etal;《LWT - Food Science and Technology》;20150901;第65卷;第840-844页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107260704A (zh) | 2017-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107260704B (zh) | 一种粪肠球菌微胶囊及其制备方法 | |
| Liao et al. | Oligosaccharides as co-encapsulating agents: effect on oral Lactobacillus fermentum survival in a simulated gastrointestinal tract | |
| Silva et al. | Symbiotic microencapsulation to enhance Lactobacillus acidophilus survival | |
| Shi et al. | Encapsulation of probiotic Lactobacillus bulgaricus in alginate–milk microspheres and evaluation of the survival in simulated gastrointestinal conditions | |
| KR101918089B1 (ko) | 장내 생존율이 증대된 유산균의 코팅 방법 | |
| CN107997179B (zh) | 一种乳酸菌微胶囊的制备方法 | |
| Islam et al. | Microencapsulation of live probiotic bacteria | |
| CN110025638B (zh) | 壳聚糖‐羧甲基纤维素钠层层自组装益生菌微囊及其制备 | |
| Abbaszadeh et al. | The effect of alginate and chitosan concentrations on some properties of chitosan‐coated alginate beads and survivability of encapsulated Lactobacillus rhamnosus in simulated gastrointestinal conditions and during heat processing | |
| Mandal et al. | Enhancement of survival of alginate‐encapsulated Lactobacillus casei NCDC 298 | |
| Zanjani et al. | Promoting probiotics survival by microencapsualtion with Hylon starch and genipin cross-linked coatings in simulated gastro-intestinal condition and heat treatment | |
| Xing et al. | Effect of porous starch concentrations on the microbiological characteristics of microencapsulated Lactobacillus acidophilus | |
| Vivek | Use of encapsulated probiotics in dairy based foods | |
| CN106617093B (zh) | 耐酸、稳定的益生菌微胶囊及其制备方法和应用 | |
| CN110367542B (zh) | 一种在肠道中缓慢释放的益生菌微胶囊及其制备方法 | |
| CN114287632A (zh) | 一种菊粉益生菌微胶囊的制备方法 | |
| Xing et al. | Effect of different coating materials on the biological characteristics and stability of microencapsulated Lactobacillus acidophilus | |
| CN114176227A (zh) | 一种海藻酸钠包裹的层层自组装益生菌微胶囊及其制备方法 | |
| CN112335884A (zh) | 一种新型益生菌微球及其制备方法 | |
| CN108048349B (zh) | 副干酪乳杆菌n1115包埋菌粉的制备方法及其应用 | |
| Panghal et al. | Microencapsulation for delivery of probiotic bacteria | |
| CN103992997B (zh) | 一种利用壳聚糖∕黄原胶制备双歧杆菌微胶囊的方法及应用 | |
| CN111514112B (zh) | 一种利用喷雾干燥技术制备肠溶复合微胶囊的方法 | |
| Shi et al. | Milk-alginate microspheres: Protection and delivery of Enterococcus faecalis HZNU P2 | |
| CN104970368B (zh) | 一种具有高存活率的耐胃酸型地衣芽孢杆菌微胶囊的制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |